ASCO: Adding Atezolizumab to Cabozantinib No Benefit in Advanced Renal Cancer

FRIDAY, June 9, 2023 -- For patients with locally advanced or metastatic renal cell carcinoma with disease progression on or after immune checkpoint inhibitor treatment, the addition of atezolizumab to cabozantinib does not improve clinical...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news